New drug tested to help transplanted kidneys last longer

NCT ID NCT03663335

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested a new antibody drug called CFZ533 to see if it could prevent organ rejection in kidney transplant patients as well as or better than the standard medication, tacrolimus. It involved 418 adults who had recently received a transplant or were maintaining a transplant from 6-24 months prior. The trial was designed to compare safety and effectiveness over 12 months but was stopped early after an interim analysis.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Los Angeles, California, 90033, United States
Novartis Investigative Site

San Francisco, California, 94143 0116, United States
Novartis Investigative Site

Aurora, Colorado, 80045, United States
Novartis Investigative Site

Chicago, Illinois, 60611, United States
Novartis Investigative Site

Chicago, Illinois, 60612, United States
Novartis Investigative Site

Kansas City, Kansas, 66103, United States
Novartis Investigative Site

Baltimore, Maryland, 21201, United States
Novartis Investigative Site

Boston, Massachusetts, 02114, United States
Novartis Investigative Site

Detroit, Michigan, 48202 2689, United States
Novartis Investigative Site

St Louis, Missouri, 63110, United States
Novartis Investigative Site

Durham, North Carolina, 27710, United States
Novartis Investigative Site

Cincinnati, Ohio, 45219, United States
Novartis Investigative Site

Cincinnati, Ohio, 45267-0585, United States
Novartis Investigative Site

Dallas, Texas, 75390, United States
Novartis Investigative Site

Seattle, Washington, 98195, United States
Novartis Investigative Site

Buenos Aires, W3400ABH, Argentina
Novartis Investigative Site

Corrientes, W3400, Argentina
Novartis Investigative Site

Córdoba, X5016KEH, Argentina
Novartis Investigative Site

Camperdown, New South Wales, 2050, Australia
Novartis Investigative Site

Adelaide, South Australia, 5000, Australia
Novartis Investigative Site

Clayton, Victoria, 3168, Australia
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, 90020-090, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 04038-002, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 05403 000, Brazil
Novartis Investigative Site

Vancouver, British Columbia, V6Z 1Y6, Canada
Novartis Investigative Site

Prague, 146 24, Czechia
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Créteil, 94010, France
Novartis Investigative Site

Grenoble, 38043, France
Novartis Investigative Site

Lyon, 69003, France
Novartis Investigative Site

Nantes, 44093, France
Novartis Investigative Site

Paris, 75015, France
Novartis Investigative Site

Toulouse, 31054, France
Novartis Investigative Site

Tours, 37044, France
Novartis Investigative Site

Regensburg, Bavaria, 93053, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Dresden, 01307, Germany
Novartis Investigative Site

Erlangen, 91054, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Hamburg, 20246, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

Budapest, H-1083, Hungary
Novartis Investigative Site

Debrecen, 4032, Hungary
Novartis Investigative Site

Milan, MI, 20132, Italy
Novartis Investigative Site

Roma, RM, 00133, Italy
Novartis Investigative Site

Nagakute, Aichi-ken, 480-1195, Japan
Novartis Investigative Site

Nagoya, Aichi-ken, 466-8650, Japan
Novartis Investigative Site

Sapporo, Hokkaido, 060 8648, Japan
Novartis Investigative Site

Sapporo, Hokkaido, 060-8604, Japan
Novartis Investigative Site

Yokohama, Kanagawa, 232 0024, Japan
Novartis Investigative Site

Tomigusuku, Okinawa, 9010224, Japan
Novartis Investigative Site

Suita, Osaka, 565 0871, Japan
Novartis Investigative Site

Kumamoto, 861-8520, Japan
Novartis Investigative Site

Osaka, 545-8586, Japan
Novartis Investigative Site

Riga, LV 1002, Latvia
Novartis Investigative Site

Rotterdam, South Holland, 3015 GD, Netherlands
Novartis Investigative Site

Groningen, 9713 GZ, Netherlands
Novartis Investigative Site

Utrecht, 3584CX, Netherlands
Novartis Investigative Site

Oslo, 0424, Norway
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Palma de Mallorca, Balearic Islands, 07120, Spain
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08003, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08036, Spain
Novartis Investigative Site

Zaragoza, 50009, Spain
Novartis Investigative Site

Gothenburg, 413 45, Sweden
Novartis Investigative Site

Uppsala, 751 85, Sweden
Novartis Investigative Site

Bern, 3010, Switzerland
Novartis Investigative Site

Glasgow, G51 4TF, United Kingdom
Novartis Investigative Site

London, SW17 0QT, United Kingdom
Novartis Investigative Site

Manchester, M13 9WL, United Kingdom

Conditions

Explore the condition pages connected to this study.

KIDNEY TRANSPLANTATION